Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Morgan Stanley Downgrades Cyteir Therapeutics to Underweight, Lowers Price Target to $2

Author: Benzinga Newsdesk | February 03, 2023 06:20am
Morgan Stanley analyst Jeffrey Hung downgrades Cyteir Therapeutics (NASDAQ:CYT) from Equal-Weight to Underweight and lowers the price target from $4 to $2.

Posted In: CYT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist